Assessment of the relationship between synaptic density and metabotropic glutamate receptors in early Alzheimer's disease: a multi-tracer PET study
Elaheh Salardini, Ryan S. O’DelliD, Em Tchorz, Nabeel NabulsiiD, Yiyun Henry HuangiD, Richard E. CarsoniD, Christopher H. van DyckiD, Adam P. MeccaiD
Abstract
BackgroundThe pathological effects of amyloid {beta} oligomers (A{beta}o) may be mediated through the metabotropic glutamate receptor subtype 5 (mGluR5), leading to synaptic loss in Alzheimers disease (AD). Positron emission tomography (PET) studies of mGluR5 using [18F]FPEB indicate a reduction of receptor binding that is focused in the medial temporal lobe in AD. Synaptic loss due to AD measured through synaptic vesicle glycoprotein 2A (SV2A) quantification with [11C]UCB-J PET is also focused in the medial temporal lobe, but with clear widespread reductions is commonly AD-affected neocortical regions. In this study, we used [18F]FPEB and [11C]UCB-J PET to investigate the relationship between mGluR5 and synaptic density in early AD. MethodsFifteen amyloid positive participants with early AD and 12 amyloid negative, cognitively normal (CN) participants underwent PET scans with both [18F]FPEB to measure mGluR5 and [11C]UCB-J to measure synaptic density. Parametric DVR images using equilibrium methods were generated from dynamic. For [18F]FPEB PET, DVR was calculated using equilibrium methods and a cerebellum reference region. For [11C]UCB-J PET, DVR was calculated with a simplified reference tissue model - 2 and a whole cerebellum reference region. ResultA strong positive correlation between mGluR5 and synaptic density was present in the hippocampus for participants with AD (r = 0.81, p < 0.001) and in the CN group (r = 0.74, p = 0.005). In the entorhinal cortex, there was a strong positive correlation between mGluR5 and synaptic in the AD group (r = 0.85, p <0.001), but a weaker non-significant correlation in the CN group (r = 0.36, p = 0.245). Exploratory analyses within and between other brain regions suggested significant positive correlations between mGluR5 in the medial temporal lobe and synaptic density in a broader set of commonly AD-affected regions. ConclusionMedial temporal loss of mGluR5 in AD is associated with synaptic loss in both medial temporal regions and more broadly in association cortical regions, indicating that mGluR5 mediated A{beta}o toxicity may lead to early synaptic loss more broadly in AD-affected networks. In CN individuals, an isolated strong association between lower mGluR5 and lower synaptic density may indicate non-AD related synaptic loss.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 8
- FWCI
- 4.54
- Field percentile
- top 5%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hippocampal mGluR5 levels are comparable in Alzheimer's and control brains, and divergently influenced by amyloid and tau in control brain
Junlong Wang, Serena Savodalli, … Ruiqing Ni·bioRxiv·May 25, 2024
- Associations between fluid biomarkers and PET imaging (UCB-J) of synaptic pathology in Alzheimer's disease
Johanna Nilsson, Adam P. Mecca, … Ann Brinkmalm·Alzheimer s & DementiaPeer-reviewed·Jul 1, 2025
- Shedding light on left hippocampal mGlu5 in Alzheimer's disease
Charleine Zussy, Magalie Mathias, … Laurent Givalois·bioRxiv·Oct 3, 2025
- Aberrant Connectivity Across the Lifespan in a Mouse Model of Alzheimer's disease and Rescue by mGluR5 Modulator Treatment
Francesca Mandino, Xilin Shen, … Evelyn M. R. Lake·bioRxiv·Dec 15, 2023
- Imaging synaptic density in ageing and Alzheimer's Disease with -SynVesT-1
Joseph Giorgio, David N. Soleimani‐Meigooni, … William J. Jagust·bioRxiv·Oct 23, 2024
- Amyloid-β1-42 oligomers enhance mGlu5R-dependent synaptic weakening via NMDAR activation and complement C3aR/C5aR signaling
Ai Na Ng, Eric W. Salter, … Graham L. Collingridge·bioRxiv·Oct 24, 2022